TY - JOUR
T1 - Practical considerations for dysphonia caused by inhaled corticosteroids
AU - Galván, César A.
AU - Guarderas, Juan Carlos
PY - 2012/9
Y1 - 2012/9
N2 - Inhaled corticosteroid (ICS) therapy has become standard in the treatment of asthma. A common local adverse effect of ICS therapy is dysphonia, which has been reported to affect 5% to 58% of patients. Although causes of dysphonia associated with ICS therapy have been underinvestigated, it may result from deposition of an active ICS in the oropharynx during administration, which then causes myopathy or a mucosal effect in the laryngopharynx. Use of ICS should be considered during any evaluation of dysphonia. We recommend using the lowest effective dosage of ICS, administering medication with a spacer, gargling, rinsing the mouth and washing the face after inhalation, and washing the spacer. If dysphonia develops despite these interventions, ICS use should be suspended until symptoms resolve, provided that asthma control is not compromised.
AB - Inhaled corticosteroid (ICS) therapy has become standard in the treatment of asthma. A common local adverse effect of ICS therapy is dysphonia, which has been reported to affect 5% to 58% of patients. Although causes of dysphonia associated with ICS therapy have been underinvestigated, it may result from deposition of an active ICS in the oropharynx during administration, which then causes myopathy or a mucosal effect in the laryngopharynx. Use of ICS should be considered during any evaluation of dysphonia. We recommend using the lowest effective dosage of ICS, administering medication with a spacer, gargling, rinsing the mouth and washing the face after inhalation, and washing the spacer. If dysphonia develops despite these interventions, ICS use should be suspended until symptoms resolve, provided that asthma control is not compromised.
UR - http://www.scopus.com/inward/record.url?scp=84866387952&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84866387952&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2012.06.022
DO - 10.1016/j.mayocp.2012.06.022
M3 - Review article
C2 - 22958993
AN - SCOPUS:84866387952
SN - 0025-6196
VL - 87
SP - 901
EP - 904
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 9
ER -